{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:42Z","timestamp":1791632262131,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00432-014-1853-6","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T15:32:42Z","timestamp":1413387162000},"page":"749-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients"],"prefix":"10.1007","volume":"141","author":[{"given":"Tatjana I.","family":"Gabbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Felsenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"1853_CR1","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580\u20138587. doi: 10.1200\/JCO.2005.02.8670","journal-title":"J Clin Oncol"},{"key":"1853_CR2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","volume":"44","author":"T Boonyapakorn","year":"2008","unstructured":"Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44:857\u2013869","journal-title":"Oral Oncol"},{"key":"1853_CR3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","volume":"139","author":"VM Cartsos","year":"2008","unstructured":"Cartsos VM, Zhu S, Zavras AI (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139:23\u201330","journal-title":"J Am Dent Assoc"},{"key":"1853_CR4","first-page":"295","volume":"2","author":"GA Clines","year":"2004","unstructured":"Clines GA, Guise TA (2004) Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2:295\u2013302","journal-title":"Clin Adv Hematol Oncol"},{"key":"1853_CR5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","volume":"21","author":"A Corso","year":"2007","unstructured":"Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545\u20131548","journal-title":"Leukemia"},{"key":"1853_CR6","unstructured":"EU Law Directive 2010\/84\/EU of the European Parliament and of the Council of 15 December 2010. http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/dir_2010_84\/dir_2010_84_en.pdf . http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/dir_2010_84\/dir_2010_84_en.pdf . Accessed 27 June 2014"},{"key":"1853_CR7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.joms.2008.12.004","volume":"67","author":"TB Dodson","year":"2009","unstructured":"Dodson TB (2009) Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:44\u201352. doi: 10.1016\/j.joms.2008.12.004","journal-title":"J Oral Maxillofac Surg"},{"key":"1853_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99\u2013102 discussion 199\u2013102","journal-title":"N Engl J Med"},{"key":"1853_CR9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","volume":"49","author":"FH Ebetino","year":"2011","unstructured":"Ebetino FH et al (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20\u201333. doi: 10.1016\/j.bone.2011.03.774","journal-title":"Bone"},{"key":"1853_CR10","unstructured":"FDA (2014) US Food and Drug Administration. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm . Accessed 09 September 2014"},{"key":"1853_CR11","unstructured":"Federal Statistical Office. German Statistical Yearbook 2014. https:\/\/www.destatis.de . Accessed 03 July 2014"},{"key":"1853_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0037-1621677","volume":"21","author":"D Felsenberg","year":"2012","unstructured":"Felsenberg D, Lopez S, Gabbert T, Hoffmeister B (2012) Osteonecrosis of the jaw in patients with osteoporosis. Osteologie 21:207\u2013212","journal-title":"Osteologie"},{"key":"1853_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.critrevonc.2010.07.017","volume":"79","author":"P Hadji","year":"2011","unstructured":"Hadji P, Gnant M, Aapro M, Lipton A, Coleman R (2011) Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol 79:175\u2013188. doi: 10.1016\/j.critrevonc.2010.07.017","journal-title":"Crit Rev Oncol Hematol"},{"key":"1853_CR14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826\u2013836. doi: 10.1359\/jbmr.080205","journal-title":"J Bone Miner Res"},{"key":"1853_CR15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.2010.05771.x","volume":"1218","author":"AO Hoff","year":"2011","unstructured":"Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF (2011) Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann NY Acad Sci 1218:47\u201354. doi: 10.1111\/j.1749-6632.2010.05771.x","journal-title":"Ann NY Acad Sci"},{"key":"1853_CR16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/pds.1634","volume":"17","author":"F Hoffmann","year":"2008","unstructured":"Hoffmann F, Jung TI, Felsenberg D, Glaeske G (2008) Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiol Drug Saf 17:896\u2013903. doi: 10.1002\/pds.1634","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1853_CR17","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","volume":"18","author":"F Jadu","year":"2007","unstructured":"Jadu F, Lee L, Pharoah M, Reece D, Wang L (2007) A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18:2015\u20132019. doi: 10.1093\/annonc\/mdm370","journal-title":"Ann Oncol"},{"key":"1853_CR18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00432-009-0662-9","volume":"136","author":"TI Jung","year":"2010","unstructured":"Jung TI, Hoffmann F, Glaeske G, Felsenberg D (2010) Disease-specific risk for an osteonecrosis of the jaw under bisphosphonate therapy. J Cancer Res Clin Oncol 136:363\u2013370. doi: 10.1007\/s00432-009-0662-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"1853_CR19","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3109\/00016357.2013.764007","volume":"71","author":"TB Kruger","year":"2013","unstructured":"Kruger TB, Sharikabad MN, Herlofson BB (2013) Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting. Acta Odontol Scand 71:1386\u20131390. doi: 10.3109\/00016357.2013.764007","journal-title":"Acta Odontol Scand"},{"key":"1853_CR20","author":"RR McKay","year":"2014","unstructured":"McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK (2014) Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma. Eur Urol. doi: 10.1016\/j.eururo.2014.02.040","journal-title":"Eur Urol"},{"key":"1853_CR21","unstructured":"Rote Liste Rote Liste Service GmbH. www.rote-liste.de . Accessed 27 June 2014"},{"key":"1853_CR22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00784-013-1012-5","volume":"18","author":"P Rugani","year":"2014","unstructured":"Rugani P, Luschin G, Jakse N, Kirnbauer B, Lang U, Acham S (2014) Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer. Clin Oral Invest 18:401\u2013407. doi: 10.1007\/s00784-013-1012-5","journal-title":"Clin Oral Invest"},{"key":"1853_CR23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0278-2391(09)01309-3","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update. J Oral Maxillofac Surg 67:2\u201312. doi: 10.1016\/j.joms.2009.01.009","journal-title":"J Oral Maxillofac Surg"},{"key":"1853_CR24","first-page":"541","volume-title":"Harrison\u2019s principles of internal medicine, vol I","author":"HI Scher","year":"2005","unstructured":"Scher HI, Motzer RJ (2005) Bladder and renal cell carcinomas. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) Harrison\u2019s principles of internal medicine, vol I, 16th edn. McGraw-Hill Companies, New York, pp 541\u2013543","edition":"16"},{"key":"1853_CR25","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2013.48.6837","volume":"31","author":"CL Shapiro","year":"2013","unstructured":"Shapiro CL (2013) Bisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspective. J Clin Oncol 31:2648\u20132650. doi: 10.1200\/JCO.2013.48.6837","journal-title":"J Clin Oncol"},{"key":"1853_CR26","doi-asserted-by":"crossref","unstructured":"Sharma D et al. (2013) Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect Vascular cell 5:1 doi: 10.1186\/2045-824X-5-1","DOI":"10.1186\/2045-824X-5-1"},{"key":"1853_CR27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.joms.2013.06.221","volume":"72","author":"M Ulmner","year":"2014","unstructured":"Ulmner M, Jarnbring F, Torring O (2014) Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 72:76\u201382. doi: 10.1016\/j.joms.2013.06.221","journal-title":"J Oral Maxillofac Surg"},{"key":"1853_CR28","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.eururo.2008.06.070","volume":"54","author":"C Walter","year":"2008","unstructured":"Walter C et al (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54:1066\u20131072. doi: 10.1016\/j.eururo.2008.06.070","journal-title":"Eur Urol"},{"key":"1853_CR29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","volume":"66","author":"JH Wessel","year":"2008","unstructured":"Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625\u2013631. doi: 10.1016\/j.joms.2007.11.032","journal-title":"J Oral Maxillofac Surg"},{"key":"1853_CR30","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/jnci\/djm025","volume":"99","author":"GS Wilkinson","year":"2007","unstructured":"Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS (2007) Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 99:1016\u20131024","journal-title":"J Natl Cancer Inst"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1853-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-014-1853-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-014-1853-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T06:49:41Z","timestamp":1565938181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-014-1853-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s00432-014-1853-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}